Valneva SE

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

09 Apr 2025 00:00:00 By Nasdaq GlobeNewswire

Valneva SE Shareholding Declaration - March 2025

03 Apr 2025 10:45:00 By Nasdaq GlobeNewswire

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

01 Apr 2025 10:45:00 By Nasdaq GlobeNewswire

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

31 Mar 2025 00:00:00 By Nasdaq GlobeNewswire

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

26 Mar 2025 12:00:00 By Nasdaq GlobeNewswire

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

25 Mar 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

24 Mar 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

20 Mar 2025 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: February 28, 2025

05 Mar 2025 11:00:00 By Nasdaq GlobeNewswire

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

03 Mar 2025 00:00:00 By Nasdaq GlobeNewswire

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

28 Feb 2025 10:45:00 By Nasdaq GlobeNewswire

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

18 Feb 2025 00:00:00 By Nasdaq GlobeNewswire

Shareholding declaration Valneva SE - January 2025

06 Feb 2025 11:00:00 By Nasdaq GlobeNewswire

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

05 Feb 2025 00:00:00 By Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million 

30 Jan 2025 10:45:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

22 Jan 2025 10:45:00 By Nasdaq GlobeNewswire

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

20 Jan 2025 10:45:00 By Nasdaq GlobeNewswire

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

06 Jan 2025 10:45:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: December 31, 2024

03 Jan 2025 11:00:00 By Nasdaq GlobeNewswire

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

19 Dec 2024 01:00:00 By Nasdaq GlobeNewswire